Hematologic Oncology

Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.

Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

The Medicines and Healthcare Products Regulatory Agency has approved zanubrutinib in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20–based therapy.

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

First-line ibrutinib plus prednisone did not improve response rates compared with placebo plus prednisone in patients with chronic graft-vs-host disease, failing to meet the primary end point of the phase 3 iNTEGRATE trial.

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.

Olutasidenib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a recommended targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

Moxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.